Д.В. Перепечин

Hormone therapy (HT) for prostate cancer (PCa) is the first line drug therapy for metastatic prostate cancer. The time between the onset of hormonal medications and the development of hormone-resistance is about 12-18 months, with 15-20% of patients with tumor primary resistant to HT. As a second-line chemotherapy various schemes with cytotoxic drugs have been proposed: mitoxantrone + prednisone, estramustine, estramustine + vinblastine, or vinorelbine +. Large randomized trials have proved schemes including docetaxel to be most efficient.